MX2020001513A - Agentes de union a clec9a y su uso. - Google Patents

Agentes de union a clec9a y su uso.

Info

Publication number
MX2020001513A
MX2020001513A MX2020001513A MX2020001513A MX2020001513A MX 2020001513 A MX2020001513 A MX 2020001513A MX 2020001513 A MX2020001513 A MX 2020001513A MX 2020001513 A MX2020001513 A MX 2020001513A MX 2020001513 A MX2020001513 A MX 2020001513A
Authority
MX
Mexico
Prior art keywords
binding agents
clec9a binding
clec9a
agents
present
Prior art date
Application number
MX2020001513A
Other languages
English (en)
Inventor
Erik Depla
Jan Tavernier
Nikolai Kley
Lenart Zabeau
Original Assignee
Orionis Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orionis Biosciences Inc filed Critical Orionis Biosciences Inc
Publication of MX2020001513A publication Critical patent/MX2020001513A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

La presente invencion se refiere, en parte, a agentes que se unen Clec9A y su uso como agentes de diagnostico y terapeuticos. La presente invencion se relaciona ademas con composiciones farmacéuticas que comprenden los agentes de union a Clec9A y su uso para tratar diversas enfermedades.
MX2020001513A 2017-08-09 2018-08-08 Agentes de union a clec9a y su uso. MX2020001513A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762542944P 2017-08-09 2017-08-09
PCT/US2018/045742 WO2019032662A1 (en) 2017-08-09 2018-08-08 CLEC9A BINDING AGENTS AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020001513A true MX2020001513A (es) 2020-08-20

Family

ID=65272496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001513A MX2020001513A (es) 2017-08-09 2018-08-08 Agentes de union a clec9a y su uso.

Country Status (11)

Country Link
US (1) US20210024637A1 (es)
EP (1) EP3665303A4 (es)
JP (2) JP7327885B2 (es)
CN (1) CN111511764B (es)
AU (1) AU2018313810A1 (es)
BR (1) BR112020002706A2 (es)
CA (1) CA3069992A1 (es)
IL (1) IL272524A (es)
MX (1) MX2020001513A (es)
SG (1) SG11202001063QA (es)
WO (1) WO2019032662A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563141A (zh) * 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
WO2018170288A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
MX2020008208A (es) 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
FI3849614T3 (fi) * 2018-09-11 2024-02-08 Ambrx Inc Interleukiini-2-polypeptidikonjugaatteja ja niiden käyttöjä
WO2020198654A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
US20230181758A1 (en) 2019-07-03 2023-06-15 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
EP4034146A4 (en) * 2019-09-26 2024-03-06 Orionis Biosciences Inc CONJUGATED CHIMERIC PROTEINS
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
KR20230104617A (ko) * 2020-10-07 2023-07-10 드렌 바이오, 인크. 항-덱틴-1 항체 및 이의 사용 방법
IL286430A (en) 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in the treatment of diseases
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0805159D0 (en) * 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
CA2755983A1 (en) * 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Compounds and methods for modulating an immune response
EP2872158A1 (en) * 2012-05-01 2015-05-20 The University of Sydney Vaccine and uses thereof
EP2992101B1 (en) * 2013-04-29 2018-10-10 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
ITTO20130563A1 (it) * 2013-07-05 2015-01-06 Savio Spa Dispositivo per l'apertura e la chiusura di un'anta oscillante apribile verso l'esterno
EP3298131B1 (en) * 2015-05-20 2023-04-26 The Regents of The University of California Method for generating human dendritic cells for immunotherapy
JP7166923B2 (ja) * 2016-02-05 2022-11-08 オリオニス バイオサイエンシズ ビーブイ 標的療法剤およびその使用
ES2917000T3 (es) * 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
WO2018144999A1 (en) * 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof

Also Published As

Publication number Publication date
EP3665303A1 (en) 2020-06-17
JP2023060153A (ja) 2023-04-27
US20210024637A1 (en) 2021-01-28
EP3665303A4 (en) 2021-04-28
BR112020002706A2 (pt) 2020-08-25
WO2019032662A1 (en) 2019-02-14
SG11202001063QA (en) 2020-03-30
AU2018313810A1 (en) 2020-02-27
JP2020530302A (ja) 2020-10-22
IL272524A (en) 2020-03-31
KR20200047564A (ko) 2020-05-07
CN111511764B (zh) 2024-02-06
WO2019032662A8 (en) 2020-03-05
JP7327885B2 (ja) 2023-08-16
CN111511764A (zh) 2020-08-07
CA3069992A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
MX2020001513A (es) Agentes de union a clec9a y su uso.
EP4276114A3 (en) Cd20 binding single domain antibodies
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
WO2017194782A3 (en) Therapeutic targeting of non-cellular structures
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
PH12021550872A1 (en) Therapeutic compounds
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
EA201991866A1 (ru) Комбинированная терапия